AstraZeneca's Ultomiris reduces episode occurrence in NMOSD, meeting primary and secondary endpoints
In the rare disease NMOSD (neuromyelitis optica spectrum disorder), patients have attacks or relapses that may cause new onset of a range of symptoms or …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
